Trend of antimicrobial drug-susceptibility of blood isolates at an oncological center (1998-2003);Tendencia del perfil de sensibilidad antimicrobiana de los aislamientos de sangre en un hospital oncológico (1998-2003)

Salud Publica de Mexico

Volumn 47, Issue 4, 2005, Pages 288-293

  Cornejo Juárez, Patricia ^a   Velásquez Acosta, Consuelo ^a   Díaz González, Adriana ^a   Volkow Fernández, Patricia ^a  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

Author keywords

Antimicrobial resistance and susceptibility; Blood cultures; Trend

Indexed keywords

AMIKACIN; CIPROFLOXACIN; GENTAMICIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; BACTERIUM CULTURE; BACTERIUM ISOLATION; BLOOD CULTURE; CANCER PATIENT; FEMALE; GRAM POSITIVE BACTERIUM; HIGH RISK PATIENT; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; STRAIN DIFFERENCE; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; BACTERIA; BETA-LACTAM RESISTANCE; CANCER CARE FACILITIES; CEFTAZIDIME; CIPROFLOXACIN; CROSS INFECTION; DATA INTERPRETATION, STATISTICAL; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, FUNGAL; ESCHERICHIA COLI; HUMANS; KLEBSIELLA; MEXICO; MICROBIAL SENSITIVITY TESTS; OXACILLIN; PENICILLIN RESISTANCE; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS EPIDERMIDIS; YEASTS;

EID: 27644482280     PISSN: 00363634     EISSN: 16067916     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Levy S. Multidrug resistance - a sign of the times. N Engl J Med 1998; 338: 1376-1378.
2. Wise R, Hart T, Cars O, Streulens M, Helmuth R, Huovinen P et al. Antimicrobial resistance is a major threat to public health. BMJ 1998; 317: 609-610.
3. Ronald J. Resistance patterns among nosocomial pathogens*: Trends over the past few years. Chest 2001; 119 suppl 2: S397-S404.
4. Gold HS, Moellering RC. Antimicrobial drug resistance. N Engl J Med 1996; 335: 1445-1453.
5. Acar JF, Goldstein FW. Consequences of increasing resistance to antimicrobial agents. Clin Infect Dis 1998; 27 (S): 125-130.
6. Patterson JE. Hospital-acquired infections: Realities of risk and I resistance. Chest 2001; 119 suppl 2: S426-S430.
7. Shlaes D, Gerding D, John JF Jr, Craig WA, Bornstein DL, Duncan RA et al. Society of Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: Guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997; 25: 584-599.
8. Goldmann DA, Huskins WC. Control of nosocomial antimicrobial-resistant bacteria: A strategy priority for hospitals worldwide. Clin Infect Dis 1997; 24 suppl I: S139-S145.
9. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing for bacteria that grow aerobically. (Eleventh Informational Supplement). Wayne (PA): NCCLS, 2001; Document M100-S11.
10. Raymond DP, Pelletier SJ, Cabtree TD, Gleason TG, Hamm LL, Pruett TL et al. Impact of a rotating empiric antibiotic schedule on infectious mortality in an intensive care unit. Crit Care Med 2001; 29: 1101-1108.
11. Landman D, Quale JM, Mayorga D, Adedeji A, Vangala K, Ravinshankar J et al. Citywide clonal outbreak of multiresistant Acinetobacter boumanii and Pseudomonos aeruginosa in Brooklyn, NY. Arch Intern Med 2002; 162: 1515-1520.
12. Goldmann DA, Weinstein RA, Wenzel RP, Tublan OC, Duma RJ, Gaynes RP et al. Strategies to prevent and control the emergence and spread of antimicrobial resistant microorganisms in hospitals. A challenge to hospital leadership. JAMA 1996; 275: 234-240.
13. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: Comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999; 43: 1379-1382.
14. Kato-Maeda M, Bautista-Alavez A, Montes de Oca-Rolón AL, Ramos-Hinojosa A, Ponce de Leon A, Bobadilla del Valle M et al. Tendencia en el incremento de la resistencia antimicrobiana en organismos causantes de bacteremia en un hospital de tercer nivel: 1995-2000. Rev Invest Clin 2003; 55: 600-605.
15. Calderón-Jaimes E, Espinosa de los Monteros LE, Avila-Beltrán R. Epidemiology of drug resistance: The case of Staphylococcus aureus and coagulase-negative staphylococci infections. Salud Publica Mex 2002; 44: 108-112.
16. Calderón-Jaimes E, Arredondo-García JL, Aguilar-Ituarte F, García-Roca P. In vitro antimicrobial susceptibility in clinical isolates of Enterococcus species. Salud Publica Mex 2003; 45: 96-101.
17. Sifuentes-Osornio J, Ponce de León A, Muñoz-Trejo T, Villalobos-Zapata Y, Ontiveros-Rodríguez C, Gómez-Roldan C. Antimicrobial susceptibility patterns and high-level gentamicin resistance among enterococci isolated in a Mexican tertiary care center. Rev Invest Clin 1996; 48: 91-96.
18. Linden PK, Moellering RC, Wood CA, Rehm SJ, Flaherty J, Bompart F et al, for the Synercid emergency-use study group. Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin. Clin Infect Dis 2001; 33: 1816-1823.
19. Anaissie E. Opportunistic mycoses in the immunocompromised host: Experience at a cancer center and review. Clin Infect Dis 1992; 14 suppl 1: S43-S53.
20. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-751.
21. Recommendations for preventing the spread of vancomycin resistance recommendations of the hospital infection control practices advisory committee (HICPAC): MMWR Morb Mortal Wkly Rep 1995; 44 (RR12): 1-13.